These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 23528218)

  • 41. Vemurafenib-associated neutrophilic panniculitis: An emergent adverse effect of variable severity.
    Maldonado-Seral C; Berros-Fombella JP; Vivanco-Allende B; Coto-Segura P; Vazquez-Lopez F; Perez-Oliva N
    Dermatol Online J; 2013 Apr; 19(4):16. PubMed ID: 24021375
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Identification of multiple mechanisms of resistance to vemurafenib in a patient with BRAFV600E-mutated cutaneous melanoma successfully rechallenged after progression.
    Romano E; Pradervand S; Paillusson A; Weber J; Harshman K; Muehlethaler K; Speiser D; Peters S; Rimoldi D; Michielin O
    Clin Cancer Res; 2013 Oct; 19(20):5749-57. PubMed ID: 23948972
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Vemurafenib in BRAFV600 mutated metastatic melanoma: a subanalysis of the Italian population of a global safety study.
    Del Vecchio M; Ascierto PA; Mandalà M; Sileni VC; Maio M; Di Guardo L; Simeone E; Queirolo P
    Future Oncol; 2015; 11(9):1355-62. PubMed ID: 25952781
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Vemurafenib (RG67204, PLX4032): a potent, selective BRAF kinase inhibitor.
    Patrawala S; Puzanov I
    Future Oncol; 2012 May; 8(5):509-23. PubMed ID: 22646766
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Acute kidney injury in patients with severe rash on vemurafenib treatment for metastatic melanomas.
    Regnier-Rosencher E; Lazareth H; Gressier L; Avril MF; Thervet E; Dupin N
    Br J Dermatol; 2013 Oct; 169(4):934-8. PubMed ID: 23909652
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Vemurafenib and radiosensitization.
    Boussemart L; Boivin C; Claveau J; Tao YG; Tomasic G; Routier E; Mateus C; Deutsch E; Robert C
    JAMA Dermatol; 2013 Jul; 149(7):855-7. PubMed ID: 23699661
    [TBL] [Abstract][Full Text] [Related]  

  • 47. New insights into renal toxicity of the B-RAF inhibitor, vemurafenib, in patients with metastatic melanoma.
    Teuma C; Perier-Muzet M; Pelletier S; Nouvier M; Amini-Adl M; Dijoud F; Duru G; Thomas L; Fouque D; Laville M; Dalle S
    Cancer Chemother Pharmacol; 2016 Aug; 78(2):419-26. PubMed ID: 27371224
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The European Medicines Agency review of vemurafenib (Zelboraf®) for the treatment of adult patients with BRAF V600 mutation-positive unresectable or metastatic melanoma: summary of the scientific assessment of the Committee for Medicinal Products for Human Use.
    da Rocha Dias S; Salmonson T; van Zwieten-Boot B; Jonsson B; Marchetti S; Schellens JH; Giuliani R; Pignatti F
    Eur J Cancer; 2013 May; 49(7):1654-61. PubMed ID: 23481513
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Improved overall survival in melanoma with combined dabrafenib and trametinib.
    Robert C; Karaszewska B; Schachter J; Rutkowski P; Mackiewicz A; Stroiakovski D; Lichinitser M; Dummer R; Grange F; Mortier L; Chiarion-Sileni V; Drucis K; Krajsova I; Hauschild A; Lorigan P; Wolter P; Long GV; Flaherty K; Nathan P; Ribas A; Martin AM; Sun P; Crist W; Legos J; Rubin SD; Little SM; Schadendorf D
    N Engl J Med; 2015 Jan; 372(1):30-9. PubMed ID: 25399551
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Vemurafenib in the French temporary authorization for use metastatic melanoma cohort: a single-centre trial.
    Fennira F; Pagès C; Schneider P; Sidina I; Viguier M; Basset-Seguin N; Madjlessi-Ezra N; Madelaine I; Bagot M; Battistella M; Porcher R; Mourah S; Lebbé C
    Melanoma Res; 2014 Feb; 24(1):75-82. PubMed ID: 24241686
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Multiple white cysts on face and trunk of a melanoma patient treated with vemurafenib.
    Gebhardt C; Staub J; Schmieder A; Goerdt S; Utikal J
    Acta Derm Venereol; 2015 Jan; 95(1):96-7. PubMed ID: 24710689
    [No Abstract]   [Full Text] [Related]  

  • 52. Radiation recall dermatitis and radiation pneumonitis during treatment with vemurafenib.
    Forschner A; Zips D; Schraml C; Röcken M; Iordanou E; Leiter U; Weide B; Garbe C; Meier F
    Melanoma Res; 2014 Oct; 24(5):512-6. PubMed ID: 24743051
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Acantholytic dermatosis in patients treated by vemurafenib: 2 cases].
    Sabatier-Vincent M; Charles J; Pinel N; Challende I; Claeys A; Leccia MT
    Ann Dermatol Venereol; 2014 Nov; 141(11):689-93. PubMed ID: 25442474
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Interplay Between Membrane Lipid Peroxidation and Photoproduct Formation in the Ultraviolet A-Induced Phototoxicity of Vemurafenib in Skin Keratinocytes.
    Teixeira A; Morlière P; Ferreira J; Conte MA; Galmiche A; Mazière JC; Santus R; Filipe P
    Toxicol Sci; 2016 Dec; 154(2):289-295. PubMed ID: 27566444
    [TBL] [Abstract][Full Text] [Related]  

  • 55. FDA approves vemurafenib for treatment of metastatic melanoma.
    Oncology (Williston Park); 2011 Sep; 25(10):906. PubMed ID: 22010387
    [No Abstract]   [Full Text] [Related]  

  • 56. Vemurafenib for the treatment of BRAF mutant metastatic melanoma.
    Martin-Liberal J; Larkin J
    Future Oncol; 2015; 11(4):579-89. PubMed ID: 25686114
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Vemurafenib-induced neutrophilic panniculitis.
    Monfort JB; Pagès C; Schneider P; Neyns B; Comte C; Bagot M; Vignon-Pennamen MD; Viguier M; Lebbé C
    Melanoma Res; 2012 Oct; 22(5):399-401. PubMed ID: 22828248
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Vemurafenib for the treatment of melanoma.
    Jordan EJ; Kelly CM
    Expert Opin Pharmacother; 2012 Dec; 13(17):2533-43. PubMed ID: 23094782
    [TBL] [Abstract][Full Text] [Related]  

  • 59. BRIM-1, -2 and -3 trials: improved survival with vemurafenib in metastatic melanoma patients with a BRAF(V600E) mutation.
    Young K; Minchom A; Larkin J
    Future Oncol; 2012 May; 8(5):499-507. PubMed ID: 22646765
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Granuloma Annulare Secondary to Vemurafenib Therapy for Lung Adenocarcinoma.
    Jenkinson HA; Siroy AE; Choksi A
    J Drugs Dermatol; 2017 Oct; 16(10):1050-1052. PubMed ID: 29036262
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.